SEQUOIA Trial: Long-Term Safety Profile of Zanubrutinib in CLL

Tanya Siddiqi, MD, highlights long-term safety outcomes with first-line zanubrutinib (Brukinsa) in patients with chronic lymphocytic leukemia in the phase 3 SEQUOIA trial. She explains that adverse events with zanubrutinib were manageable and notes that the risk of atrial fibrillation remains low with long-term use of the BTK inhibitor.